TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22236392

Group type: EXPERIMENTAL
Intervention: Two-session psychological intervention including medical information, coping skills promotion, and a psychoeducational booklet for parents.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active control group with standard psychosocial care.
Number of subjects: 30
Study: 22236508

Group type: EXPERIMENTAL
Intervention: Invasive testing (intracoronary acetylcholine administration, fast atrial pacing)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Invasive testing
Number of subjects: 718
Study: 22237988

Group type: EXPERIMENTAL
Intervention: Mesothelin expression in BE tissue with high-grade dysplasia
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mesothelin expression in EAC tumors
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mesothelin expression in EAC tumors with BE vs. without BE
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Soluble mesothelin-related peptide (SMRP) levels in EAC patients
Number of subjects: 125

Group type: COMPARATOR
Intervention: SMRP levels in patients with acid reflux and/or BE
Number of subjects: 125
Study: 22238003

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (3 times/week; 3 sets, 6-8 repetitions at 75-80% of the 1-repetition maximum)
Number of subjects: 237
Study: 22238693

Group type: EXPERIMENTAL
Intervention: Pronto-7™ monitor
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NBM-200MP™ monitor
Number of subjects: 600
Study: 22239832

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tap test (TT)
Number of subjects: 100
Study: 22240751

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22241828

Group type: EXPERIMENTAL
Intervention: QSU-Brief questionnaire administered to Black light smokers
Number of subjects: 540
Study: 22244041

Group type: COMPARATOR
Intervention: Normal weight children (nw)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Overweight children (ow)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Obese children (ob)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Higher physical inactivity
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Wider venular diameters
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 578
Study: 22244076

Group type: EXPERIMENTAL
Intervention: Pemetrexed (standard vitamin and dexamethasone supplementation)
Number of subjects: 521
Study: 22244711

Group type: EXPERIMENTAL
Intervention: Antithrombotic medications continued
Number of subjects: 177

Group type: COMPARATOR
Intervention: Antithrombotic medications temporarily discontinued
Number of subjects: 177
Study: 22245983

Group type: EXPERIMENTAL
Intervention: Usual energy intake
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Laboratory energy intake
Number of subjects: 252
Study: 22246176

Group type: EXPERIMENTAL
Intervention: Shift work model (intensivists working 7 day shifts)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard model (one intensivist worked for 7 days, taking night call from home)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Shift work model
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Nighttime housestaff under shift work model
Number of subjects: 501
Study: 22246178

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin pretreatment in mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 22247403

Group type: EXPERIMENTAL
Intervention: Hippotherapy (45-minute sessions twice per week for 6 weeks)
Number of subjects: 16
Study: 22247754

Group type: EXPERIMENTAL
Intervention: Genetic factors assessed using the Illumina Human660 W Genotyping BeadChip
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Cohort of individuals with ICD who did not experience LTA (controls)
Number of subjects: 1006
Study: 22248486

Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3 supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cord serum 25(OH)D levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Daily vitamin D intake of 400 IU
Number of subjects: 49
Study: 22248602

Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided mini-forceps biopsies
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard cytology brushings
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard forceps biopsies
Number of subjects: 26
Study: 22248721

Group type: EXPERIMENTAL
Intervention: Platinum-based compounds (PBCs) as single agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin/carboplatin combined with taxanes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBCs combined with vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBCs combined with etoposide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBCs combined with anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBCs combined with trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin with novel targeted therapeutics
Number of subjects: 0
Study: 22249106

Group type: EXPERIMENTAL
Intervention: Tigecycline 0.75 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tigecycline 1 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tigecycline 1.25 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tigecycline (all dosages)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tigecycline 1.2 mg/kg q12h (predicted)
Number of subjects: 58
Study: 22249355

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg per day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Duloxetine in patients with major depressive disorder (MDD)
Number of subjects: 164
Study: 22249367

Group type: EXPERIMENTAL
Intervention: Activated CD169+CD14+ monocytes during rejection in group B
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Activated CD169+CD14+ monocytes during infection/inflammation in group D
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Activated monocytes before ITx in rejectors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Activated monocytes during acute cellular rejection in rejectors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Correlation of activated monocytes with allospecific CD154+ T-cytotoxic memory cells
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Correlation of activated monocytes with allospecific CD154+ B cells
Number of subjects: 56
Study: 22249430

Group type: EXPERIMENTAL
Intervention: Dacomitinib 15 mg QD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg QD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg QD
Number of subjects: 13
Study: 22250143

Group type: EXPERIMENTAL
Intervention: Virtual autopsy
Number of subjects: 285

Group type: COMPARATOR
Intervention: Medical autopsy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Any autopsy method
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Virtual autopsy only
Number of subjects: 285
Study: 22250979

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) 600/100 mg plus lamivudine and stavudine administered every 12 hours (bid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) treatment with concomitant rifampicin
Number of subjects: 18
Study: 22252944

Group type: EXPERIMENTAL
Intervention: Higher ghrelin secretion in amenorrheic athletes (AA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lower leptin secretion in amenorrheic athletes (AA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lower LH secretion in amenorrheic athletes (AA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Association of body fat with hormone levels
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Regression model findings
Number of subjects: 3
Study: 22253412

Group type: EXPERIMENTAL
Intervention: Synchronous bevacizumab and erlotinib with concurrent cisplatin and twice daily radiotherapy
Number of subjects: 29
Study: 22253485

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 65
Study: 22254197

Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 803
Study: 22256804

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vemurafenib analogue PLX4720
Number of subjects: 35
Study: 22257420

Group type: EXPERIMENTAL
Intervention: Family history of diabetes and CHD and/or stroke (Group 3)
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: Family history of diabetes alone (Group 2)
Number of subjects: 2081

Group type: COMPARATOR
Intervention: No family history of diabetes, CHD or stroke (Group 1)
Number of subjects: 2081
Study: 22258268

Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake of 1000 mg/d
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Top quintile dietary sodium consumption (>1456 mg/d)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 1000-mg/d difference in dietary sodium between brothers
Number of subjects: 286
Study: 22258271

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) with controlled ingestion of a fixed amount of gluten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal gluten-containing diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) with ingestion of <100 mg gluten/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GFD infringement detection in CD patients
Number of subjects: 0
Study: 22258485

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: QTF-Gold IT
Number of subjects: 429

Group type: COMPARATOR
Intervention: TST
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: IGRA tests (one of the tests)
Number of subjects: 429
Study: 22258545

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole 12.5 mg/day for 3 days)
Number of subjects: 16
Study: 22259028

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily dose
Number of subjects: 1
Study: 22260199

Group type: EXPERIMENTAL
Intervention: Spinal block using 10 mg 0.5% (w/v) bupivacaine
Number of subjects: 38
Study: 22261507

Group type: EXPERIMENTAL
Intervention: Normal height at age 4 years
Number of subjects: 119

Group type: COMPARATOR
Intervention: Height <-1 SD
Number of subjects: 119

Group type: COMPARATOR
Intervention: Height ≥-1 SD
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Females with normal height
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Preterm-born children with normal height
Number of subjects: 119
Study: 22262746

Group type: EXPERIMENTAL
Intervention: Everolimus, titrated to tolerability to achieve target trough concentrations of 5-15 ng/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (nontreatment cohort)
Number of subjects: 20
Study: 22263035

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5000
Study: 22263047

Group type: EXPERIMENTAL
Intervention: CP + ASA404 (1200 mg/m(2) or 1800 mg/m(2))
Number of subjects: 108

Group type: COMPARATOR
Intervention: CP alone (Carboplatin AUC 6 mg/ml•min and Paclitaxel 175 mg/m(2))
Number of subjects: 108
Study: 22264202

Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter treatment
Number of subjects: 26
Study: 22264765

Group type: EXPERIMENTAL
Intervention: ACTH-treated OMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated OMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCL12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCR5+ memory B cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCL13 and CXCL12
Number of subjects: 0
Study: 22264850

Group type: EXPERIMENTAL
Intervention: Aflibercept in the VITAL trial for advanced non-small cell lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflibercept in the VANILLA trial for metastatic pancreatic cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI in the VELOUR trial for metastatic colorectal cancer
Number of subjects: 0
Study: 22265115

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 1035
Study: 22267606

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (100 mg fixed dose for 4 weekly infusions) with a short course of steroids
Number of subjects: 23
Study: 22267607

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg intravenous loading dose followed by 2 mg/kg weekly)
Number of subjects: 15
Study: 22267687

Group type: EXPERIMENTAL
Intervention: FF/VI 400/25 μg once daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22267750

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac magnetic resonance to quantify heterogeneous myocardial tissue (gray zone) and dense core scar, along with serum high-sensitivity C-reactive protein (hsCRP) levels
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lowest tertile for both GZ and hsCRP (n=42)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Highest tertile for both GZ and hsCRP (n=32)
Number of subjects: 235
Study: 22267829

Group type: EXPERIMENTAL
Intervention: 25% human albumin at 1.25 g/kg/day for 7 days (Tier 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 25% human albumin at 0.625 g/kg/day for 7 days (Tier 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 25% human albumin at 1.875 g/kg/day for 7 days (Tier 3)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (upcoming in ALISAH II trial)
Number of subjects: 47
Study: 22268134

Group type: EXPERIMENTAL
Intervention: Subjects with ILA
Number of subjects: 2416
Study: 22269066

Group type: EXPERIMENTAL
Intervention: ADAPT system (electronic health record-embedded tool for shared goal setting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADAPT system
Number of subjects: 0
Study: 22269593

Group type: EXPERIMENTAL
Intervention: Educational intervention enhanced with positive-affect induction and self-affirmation
Number of subjects: 258

Group type: COMPARATOR
Intervention: Educational protocol alone (control)
Number of subjects: 258
Study: 22269735

Group type: EXPERIMENTAL
Intervention: Clopidogrel cessation
Number of subjects: 1
Study: 22269834

Group type: EXPERIMENTAL
Intervention: MI embedded into physiotherapy (EG1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MI added to physiotherapy (EG2)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 39
Study: 22269862

Group type: EXPERIMENTAL
Intervention: B cell depletion with rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B cell modulators such as belimumab and abatacept
Number of subjects: 0
Study: 22270258

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 31
Study: 22270330

Group type: EXPERIMENTAL
Intervention: GM-CSF (500 ug daily for 4 days starting 24 hours after each chemotherapy cycle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 20
Study: 22270480

Group type: EXPERIMENTAL
Intervention: copd-6 device
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard diagnostic spirometry
Number of subjects: 305
Study: 22271896

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 142
Study: 22272248

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (three infusions per week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard treatment of gemcitabine and erlotinib
Number of subjects: 14
Study: 22272830

Group type: EXPERIMENTAL
Intervention: Polymorphic variant GSTP1 (Ile105Val)
Number of subjects: 57
Study: 22273029

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP~T vaccine booster
Number of subjects: 182
Study: 22274724

Group type: EXPERIMENTAL
Intervention: Primary control coping (e.g., problem solving)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Secondary control coping (e.g., acceptance)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Disengagement coping (e.g., avoidance)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 327
Study: 22274965

Group type: EXPERIMENTAL
Intervention: Modified aspiration (group B, n=93)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Traditional aspiration (group A, n=66)
Number of subjects: 159
Study: 22275401

Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP (5 × 10^10 viral particles and above)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP followed by MVA ME-TRAP booster
Number of subjects: 54

Group type: COMPARATOR
Intervention: ChAd63 ME-TRAP
Number of subjects: 54
Study: 22276954

Group type: EXPERIMENTAL
Intervention: Oral methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable diacetylmorphine or injectable hydromorphone
Number of subjects: 0
Study: 22277551

Group type: EXPERIMENTAL
Intervention: Marine-derived n-3 PUFAs (highest quintile of intake)
Number of subjects: 3166

Group type: EXPERIMENTAL
Intervention: Dietary intake of α-linolenic acid
Number of subjects: 3166

Group type: EXPERIMENTAL
Intervention: Marine-derived n-3 PUFAs
Number of subjects: 3166

Group type: COMPARATOR
Intervention: n-6 PUFAs
Number of subjects: 3166
Study: 22277685

Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin T (cTnT) ≥0.01 ng/mL
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Impaired renal function (chronic kidney disease stage 3-5)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Elevated cTnT
Number of subjects: 254

Group type: COMPARATOR
Intervention: Overall mortality and amputation rates
Number of subjects: 254
Study: 22280805

Group type: EXPERIMENTAL
Intervention: Hypofractionated external beam radiotherapy (55 Gy in 16 fractions at 3.4 Gy per fraction)
Number of subjects: 73
Study: 22280813

Group type: EXPERIMENTAL
Intervention: DHEA (200mg daily orally for 3 months)
Number of subjects: 8
Study: 22281249

Group type: EXPERIMENTAL
Intervention: Cardiac imaging (single-photon emission computed tomography, positron emission tomography, or 64-slice coronary computed tomography angiography)
Number of subjects: 1703

Group type: EXPERIMENTAL
Intervention: Computed tomography angiography
Number of subjects: 1703

Group type: EXPERIMENTAL
Intervention: Cardiac imaging
Number of subjects: 1703
Study: 22281388

Group type: EXPERIMENTAL
Intervention: hESC-derived retinal pigment epithelium (RPE) transplantation
Number of subjects: 2
Study: 22281797

Group type: EXPERIMENTAL
Intervention: Survival from time of diagnostic right-sided heart catheterization
Number of subjects: 2635

Group type: EXPERIMENTAL
Intervention: Idiopathic/familial PAH survival rates
Number of subjects: 2635

Group type: COMPARATOR
Intervention: Estimated survival rates using NIH equation
Number of subjects: 2635
Study: 22281831

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (5 × 10^7 plaque-forming units)
Number of subjects: 48
Study: 22282182

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SW)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Visual color stiffness assessment
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Quantitative maximum elasticity of 80 kPa (5.2 m/sec) or less
Number of subjects: 939
Study: 22282683

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 84

Group type: COMPARATOR
Intervention: G+GM
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: G-CSF and G+GM
Number of subjects: 84
Study: 22283499

Group type: EXPERIMENTAL
Intervention: Postpartum women with major depression
Number of subjects: 120
Study: 22284809

Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Silencing TGF-β1 receptors
Number of subjects: 64
Study: 22284935

Group type: EXPERIMENTAL
Intervention: D-dimer threshold < 1000 ng mL(-1) with RGS ≤ 6
Number of subjects: 678

Group type: COMPARATOR
Intervention: D-dimer threshold < 500 ng mL(-1) with RGS ≤ 6
Number of subjects: 678
Study: 22285014

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 275
Study: 22285199

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 149
Study: 22285963

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily) for 9 months
Number of subjects: 41
Study: 22286551

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 21
Study: 22286779

Group type: EXPERIMENTAL
Intervention: S9 CPAP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual CPAP pre-S9
Number of subjects: 50
Study: 22287426

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) coupled with continued medical management
Number of subjects: 180

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 180
Study: 22289660

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs) (100-400 × 10(6) cells)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs)
Number of subjects: 20
Study: 22289724

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 25 μg, 50 μg, 100 μg, and 200 μg
Number of subjects: 19
Study: 22289893

Group type: EXPERIMENTAL
Intervention: Costimulated tumor-derived donor lymphocyte (TDL) infusion
Number of subjects: 8
Study: 22291430

Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise stress echocardiography in patients with HFPEF
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sub-maximal exercise stress echocardiography in controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Correlation of LV afterload (arterial elastance) during exercise
Number of subjects: 21
Study: 22291490

Group type: EXPERIMENTAL
Intervention: ramipril (5 mg/daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33